Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer
NCT ID: NCT02325999
Last Updated: 2014-12-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
200 participants
INTERVENTIONAL
2013-12-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESD and LRLD
The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
ESD AND LRLD
A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
Endoscopic Submucosal Dissection (ESD)
The group accept Endoscopic Submucosal Dissection only.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESD AND LRLD
A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* cT1b: Submucosal injection (+)
Exclusion Criteria
* recrudescence
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hua Meng
Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection for early gastric cancer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shu-tian ZHANG
Role: STUDY_CHAIR
Beijing Friendship Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The capital health research and development of special
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hua MENG
Role: primary
Qiu-yue ZHANG
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BeijingFHMH2013
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
ESDLD2013
Identifier Type: -
Identifier Source: org_study_id